Cleaning validation and verification in a high potent granulation suite

Published: 17-Nov-2022 Featured companies: PCI Pharma Services
Manufacturing Dosage Forms

Download the roundtable discussion for free

When manufacturing highly potent solid oral dosage forms, taking an effective approach to cleaning the equipment used is paramount. Manufacturing Chemist Editor Dr Kevin Robinson recently caught up with PCI Pharma Services process experts Ben Potter, Amala Alex and Richard Parry to learn more about cleaning validation and verification, the differences between the two … and why they’re so important. 

Download the roundtable discussion today. 

Featured companies

PCI Pharma Services: Your bridge between life-changing therapies and patients.
See more

You may also like

Manufacturing

An integrated path: how CDMOs are reshaping complex drug development

Read more
The pharmaceutical CDMO sector is rapidly evolving toward integrated, end-to-end partnerships that align development, manufacturing, packaging and supply to meet the growing complexity, cost pressures and scalability demands of advanced biologics and precision therapies

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  4. See. Try. Believe. Experience the Lyza 7000 FTIR with a 70-day risk free trial Laboratories can now evaluate the Lyza 7000 FTIR spectrometer in their own environment through a new 70-day, no-cost, no-risk trial program. The initiative allows teams to run real samples, follow existing SOPs, and fully explore the instrument’s capabilities before making a purchase decision
  5. Andelyn Biosciences and ENCell partner to create US-APAC gene therapy manufacturing corridor The company has signed a collaboration agreement with South Korea's ENCell to establish a dual-hemisphere manufacturing platform linking US and Asia-Pacific facilities, enabling in-country production for regional clinical trials

Relevant companies

See more

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

An integrated path: how CDMOs are reshaping complex drug development

The pharmaceutical CDMO sector is rapidly evolving toward integrated, end-to-end partnerships that align development, manufacturing, packaging and supply to meet the growing complexity, cost pressures and scalability demands of advanced biologics and precision therapies
Manufacturing

Rare diseases and the integrated CDMO support system

In medicine, rarity is both a curse and a calling. When it comes to rare diseases, some may affect only a handful of families worldwide; yet the lack of scale does nothing to lessen the weight of those patients who are suffering
Manufacturing

Ultra-high potency and its impact on pharmaceutical outsourcing

This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an evolving therapeutic landscape
Manufacturing

The changing face of pharma outsourcing

CDMOs are evolving from service providers to strategic partners driving innovation and speed in drug development
Manufacturing

Agility, scale and trust: the outsourcing model driving pharma forward

Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in costly new facilities. That framing no longer fits
Manufacturing

At BIO Show in Boston, PCI Pharma Services to provide updates on new manufacturing facility

For leading CDMO, qualification activities for plant’s state-of-the-art sterile fill-finish and lyophilisation line are underway, with GMP production commencing summer 2025
Manufacturing

Targeted protein degraders: transforming oral therapeutics

Targeted protein degraders (TPDs) are redefining modern drug discovery and development, offering a revolutionary approach to treating diseases that were once considered to be untreatable
Subscribe now